Prilenia Therapeutics B.V. and Ferrer have received United States Food and Drug Administration clearance to initiate the PREVAiLS pivotal Phase 3 trial of pridopidine in amyotrophic lateral sclerosis. The randomized, placebo-controlled study will enroll 500 patients with early-stage, rapidly progressing ALS across up to 60 global centers. Recruitment in the United States is set to begin in early 2026. The study is designed to confirm promising subgroup efficacy signals previously observed in the HEALEY ALS Platform trial.
Why the PREVAiLS trial may reflect a shift in ALS clinical development norms
The design of the PREVAiLS study represents a deliberate departure from earlier broad-based ALS trials that often targeted heterogeneous patient populations with limited biomarker guidance. Instead, Prilenia Therapeutics B.V. and Ferrer are pursuing a targeted strategy that enrolls participants within 18 months of symptom onset and who meet El Escorial diagnostic criteria for probable or definite ALS. This cohort aligns with the population that showed functional benefit and survival advantage in post-hoc analyses of the HEALEY trial.
The emphasis on functional preservation—particularly speech, respiratory function, and bulbar control—signals a redefinition of clinically meaningful outcomes in ALS. While survival remains a key endpoint, trial designers increasingly recognize that slowing the deterioration of motor function and quality of life domains can be as impactful in the eyes of patients, caregivers, and clinicians.
In this context, PREVAiLS reflects an evolution in ALS drug development toward granular phenotyping, multidomain endpoints, and earlier-stage intervention. By combining this strategy with biomarker data and patient-reported outcomes, the study may set a precedent for future neurodegenerative trial designs beyond ALS.
What sets pridopidine’s S1R mechanism apart from existing ALS therapies
Pridopidine is an oral, twice-daily sigma-1 receptor (S1R) agonist that activates neuroprotective cellular pathways believed to be impaired in ALS. Unlike riluzole, which modulates glutamate release, or edaravone, which targets oxidative stress, pridopidine is designed to stabilize endoplasmic reticulum function, mitochondrial dynamics, and synaptic integrity.
These mechanisms are particularly relevant in early ALS pathogenesis, where neuronal dysfunction precedes irreversible motor neuron death. This makes S1R modulation theoretically more potent when deployed early in the disease course—a hypothesis that PREVAiLS is structured to test directly.
The 48-week double-blind period, followed by a 48-week open-label extension, allows investigators to assess both immediate and sustained benefit. Importantly, the trial incorporates adjusted ALSFRS-R scoring for mortality, capturing progression dynamics even among patients who die during the study. This adjustment reflects a growing awareness that raw ALSFRS-R data may understate drug benefit in fast-progressing populations.
How PREVAiLS compares with other late-stage ALS programs
Compared with other Phase 3 programs in ALS, such as those evaluating AMX0035, tofersen, or CNM-Au8, the PREVAiLS trial stands out for its tight alignment between mechanism of action, patient phenotype, and prior efficacy signal. Most other late-stage trials have tested broader populations or lacked robust data-driven enrichment strategies. PREVAiLS, by contrast, is purpose-built to confirm a survival and function-preserving signal seen in a defined subgroup.
This approach is not without risk. Subgroup findings from HEALEY were statistically significant but not powered for standalone decision-making. However, the consistency of benefit across motor, respiratory, bulbar, and speech domains strengthens the rationale for a focused confirmatory trial.
By embedding exploratory endpoints such as plasma biomarkers and patient-reported communication scores, PREVAiLS also builds a foundation for real-world applicability and payer value assessment, should the drug move toward approval.
Why timing of treatment may be the differentiating factor
Clinicians observing the ALS space believe that the timing of therapy initiation may ultimately determine whether a candidate drug shows efficacy. Many therapies have failed not due to mechanistic failure, but because patients were too advanced to benefit. Pridopidine’s mechanism appears most relevant when there is still residual neuronal reserve to protect.
The decision to restrict enrollment to participants within 18 months of first symptom onset reflects this belief. The HEALEY subgroup data showed that even in this narrowed window, pridopidine was associated with a 57 percent improvement in median survival, doubling it from 300 to 600 days. Furthermore, respiratory decline was slowed by 62 percent and deterioration in speech articulation was reduced by more than 90 percent.
Such dramatic effects, while derived from nominal p-values, suggest that early neuroprotection could be a viable treatment approach if validated in PREVAiLS. Regulatory watchers suggest that if these signals hold in the new trial, pridopidine could potentially secure Breakthrough Therapy designation or be fast-tracked in the ALS drug pipeline.
What challenges remain for approval and commercialization
Despite the scientific and clinical rationale, multiple hurdles remain before pridopidine can become an approved therapy for ALS. First, the statistical powering of PREVAiLS must be sufficient to demonstrate robust effect size across primary and secondary endpoints. Given the high bar set by regulators after prior failures in the field, only a clearly positive dataset is likely to be persuasive.
Second, the safety and tolerability profile must hold across a longer exposure period and in a broader population. Although pridopidine has been used in over 1,600 individuals in Huntington’s disease and ALS trials, including seven-year open-label follow-ups, Phase 3 exposure in ALS remains untested.
Third, manufacturing and commercial scalability could become issues depending on trial success. Prilenia Therapeutics B.V. is a private biotech firm and will likely require further commercial infrastructure or partnerships—especially in the United States—if FDA approval is pursued. Its partnership with Ferrer may address commercialization in Europe and parts of Latin America, but global expansion would need to be mapped out rapidly.
From a payer standpoint, pridopidine will also face scrutiny on cost-effectiveness. Oral delivery and the absence of infusion costs offer advantages compared to current standards of care, but value frameworks will depend on the magnitude and durability of clinical benefit, as well as patient-reported outcomes.
What PREVAiLS could mean for the broader neurodegenerative drug landscape
Should PREVAiLS succeed, it may have implications far beyond ALS. Pridopidine is also being advanced in Huntington’s disease, with a confirmatory trial expected to launch in 2026. If both ALS and HD trials validate the drug’s efficacy, it could position pridopidine as a rare example of a disease-modifying agent with cross-indication neuroprotective benefit.
That, in turn, could accelerate broader interest in S1R agonists and shift investor focus back toward neuroprotection strategies previously considered too speculative. For developers working on Parkinson’s disease, frontotemporal dementia, or Alzheimer’s disease, the PREVAiLS outcome could be instructive.
In ALS specifically, a successful trial would likely encourage additional enriched-enrollment trials focused on early, fast-progressing patients, as well as more widespread use of functional and patient-reported endpoints in regulatory submissions.
Conclusion: A focused trial with broader significance
The PREVAiLS trial is not merely another ALS study. It is an attempt to validate a precise, mechanism-aligned therapy in a narrowly defined population, using a trial design that prioritizes functional preservation and survival. By learning from past failures and leveraging real-world clinical priorities, Prilenia Therapeutics B.V. and Ferrer may be helping reshape expectations around what is possible in ALS drug development.
If successful, PREVAiLS would not only bring pridopidine closer to market, but also establish a new benchmark for how future ALS therapies are developed, evaluated, and approved. The field will be watching closely.
What makes Prilenia’s PREVAiLS trial different from past ALS failures added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →